Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    23775961 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2
Condition: Non Small Cell Lung Carcinoma
Interventions: Drug: Pemetrexed;   Drug: Carboplatin
2 Not yet recruiting A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Condition: Lungcancer
Interventions: Drug: Binimetinib;   Drug: Pemetrexed;   Drug: Carboplatin

Study has passed its completion date and status has not been verified in more than two years.